📌 Why in News?
The Union Health Ministry has proposed amendments to the Medical Devices Rules, 2017, to promote ease of doing business. Simplification of Outsourced Sterilisation (Amendment to Rule 44): Manufacturers outsourcing sterilisation to a facility, holding a valid licence under the Medical Devices Rules, 2017, will no longer require a separate loan licence for the sterilisation activity. Traceability will be retained: manufacturers must mention the licence number of the sterilisation facility on the medical device label.
Syllabus & Relevance
Prelims: Polity & Governance — institutions, terminology and factual features connected with the development.
Mains: GS-2 — contemporary application of the relevant syllabus theme.
Current–static link: Revise the underlying institution, policy or concept together with this development.
Why it matters for India
Recognition of the European Union (Amendment to Rule 63): The European Union (EU) will be added to the list of recognised stringent regulatory jurisdictions for waiving clinical investigation requirements for certain medical devices without predicate devices in India.
Medical devices approved in the EU that meet the eligibility conditions can benefit from the waiver provisions in India.
Brings India’s regulatory framework closer to global practices.
A simpler and more predictable regulatory environment can promote investment and innovation in India’s medical-device industry.
Static Foundation
Traceability will be retained: manufacturers must mention the licence number of the sterilisation facility on the medical device label.
A six-month transition period has been provided to allow companies to modify labels, packaging and related processes.
Standardised Testing Fees: A Ninth Schedule is proposed to prescribe uniform fees for medical device testing laboratories.
It will reduce variations and uncertainty in testing charges.
Recognition of the European Union (Amendment to Rule 63): The European Union (EU) will be added to the list of recognised stringent regulatory jurisdictions for waiving clinical investigation requirements for certain medical devices without predicate devices in India.
The existing list includes the US, UK, Australia, Canada and Japan.
Medical devices approved in the EU that meet the eligibility conditions can benefit from the waiver provisions in India.
Data, Reports, Cases & Examples
The Union Health Ministry has proposed amendments to the Medical Devices Rules, 2017, to promote ease of doing business.
Simplification of Outsourced Sterilisation (Amendment to Rule 44): Manufacturers outsourcing sterilisation to a facility, holding a valid licence under the Medical Devices Rules, 2017, will no longer require a separate loan licence for the sterilisation activity.
Recognition of the European Union (Amendment to Rule 63): The European Union (EU) will be added to the list of recognised stringent regulatory jurisdictions for waiving clinical investigation requirements for certain medical devices without predicate devices in India.
India’s medical devices market is projected to grow steadily from US$ 15.2 billion in 2025 to US$ 50.1 billion by 2030.
FDI inflow in the medical and surgical appliances sector between April 2000- December 2025 stood at US$ 4.24 billion.
The National Medical Devices Policy 2023 supports India’s medical devices sector through regulatory streamlining, infrastructure, R&D, and investment promotion, boosting competitiveness and exports.
Prelims Quick Facts
The Union Health Ministry has proposed amendments to the Medical Devices Rules, 2017, to promote ease of doing business.
Simplification of Outsourced Sterilisation (Amendment to Rule 44): Manufacturers outsourcing sterilisation to a facility, holding a valid licence under the Medical Devices Rules, 2017, will no longer require a separate loan licence for the sterilisation activity.
Traceability will be retained: manufacturers must mention the licence number of the sterilisation facility on the medical device label.
A six-month transition period has been provided to allow companies to modify labels, packaging and related processes.
Standardised Testing Fees: A Ninth Schedule is proposed to prescribe uniform fees for medical device testing laboratories.
It will reduce variations and uncertainty in testing charges.
Recognition of the European Union (Amendment to Rule 63): The European Union (EU) will be added to the list of recognised stringent regulatory jurisdictions for waiving clinical investigation requirements for certain medical devices without predicate devices in India.
The existing list includes the US, UK, Australia, Canada and Japan.
Mains-only layer✍️ Open Mains Perspective & Answer FrameworkClick to expand ↓
Mains Perspective
Background and key dimensions
- Standardised Testing Fees: A Ninth Schedule is proposed to prescribe uniform fees for medical device testing laboratories.
- It will reduce variations and uncertainty in testing charges.
- Recognition of the European Union (Amendment to Rule 63): The European Union (EU) will be added to the list of recognised stringent regulatory jurisdictions for waiving clinical investigation requirements for certain medical devices without predicate devices in India.
- The existing list includes the US, UK, Australia, Canada and Japan.
- Medical devices approved in the EU that meet the eligibility conditions can benefit from the waiver provisions in India.
- Reduces unnecessary licensing and compliance requirements.
- Enables quicker availability of eligible and innovative medical devices.
- Standardised testing fees make compliance costs more predictable.
- Brings India’s regulatory framework closer to global practices.
- A simpler and more predictable regulatory environment can promote investment and innovation in India’s medical-device industry.
- The medical devices sector covers a wide range of products, including diagnostic equipment, imaging devices such as MRI and CT scanners, implants, surgical instruments, patient-monitoring equipment and in-vitro diagnostic (IVD) devices.
- India’s medical devices market is projected to grow steadily from US$ 15.2 billion in 2025 to US$ 50.1 billion by 2030.
Analytical use
- Connect the development with its institutional, policy, economic, social, environmental or security implications only where supported above.
- In a Mains answer, separate the verified development from broader evaluation and use the named evidence precisely.
Way forward
- Base recommendations on the gaps and institutional responsibilities identified in the source-grounded points.
Answer Framework
Introduction
Begin with the immediate development and identify the central institution or policy issue.
Body
- Explain the relevant static concept.
- Present the principal source-backed facts.
- Analyse significance for India and the syllabus theme.
- Discuss supported challenges or implementation gaps.
- Use one named law, report, institution, date or example from the evidence box.
Conclusion
End with a balanced, institutionally feasible way forward without making claims beyond the available evidence.
Possible Mains Question
Examine the significance of “India Proposes Medical Device Rule Changes To Boost Ease Of Business”. Discuss its key implications and the way forward.